AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie women's Health Portfolio [legacy through FY21] — U.S. reported growth YoY (%) (%)
Form 8-K Key Product Revenues Schedule
Latest, FY2021
19.1%
Period ended Dec 31, 2021
Change on a year earlier
–
History
1 years
Since FY2021
Sources
1
Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02)
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Women's Health Portfolio [legacy through FY21] — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | 19.1% | – | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
Cite this data
StockData. (2026). AbbVie Women's Health Portfolio [legacy through FY21] — U.S. reported growth YoY (%) (%), annual FY2021–FY2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta_womens_us_rep_yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.